A premarket trial of the Becton Dickinson Directigen respiratory syncytial virus membrane-based enzyme immunoassay compared the test with virus isolation for the detection of respiratory syncytial virus in 583 nasopharyngeal aspirates. After modification, the Directigen test showed a sensitivity of 83% and a specificity of 90%. It offers the potential for an efficient bedside test-without the need for any equipment-for the diagnosis of respiratory syncytial virus infection and requires only a 0.25-ml sample volume. However, for optimum reliability, freezing-thawing of samples and access to a confirmatory test were shown to be necessary.
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Respiratory syncytial virus (RSV) is the most common respiratory virus pathogen in the pediatric community (6) (7) (8) (9) itive Directigen result after freezing-thawing. Conversely, in the sample of 52 NPA which were screen test positive by the Directigen RSV test but culture negative, 16 were subsequently confirmed positive in the former test after a blocking test with bovine anti-RSV serum (supplied by the manufacturer). The other 36 specimens showing reactions that were not blocked by (bovine) anti-RSV serum were considered false positive in the Directigen test. Table 2 relates these revised Directigen test results after blocking and repeat testing with virus culture. Thus, the sensitivity and specificity of the Directigen RSV test were 83% (43 of 52) and 90% (479 of 531), respectively, after adjusting for the confirmed positives and testing of specimens which were frozen and thawed once. The diagnostic categories of these patients were further analyzed in relation to the patterns of RSV detection in both tests (Table 3 ). The highest rate of positives (45 of 104, 43%) was, as expected, seen in patients suffering from bronchiolitis or pneumonia. In patients with signs and symptoms of upper respiratory tract infection or asthma, 14% (34 of 242) were RSV positive by the Directigen test or culture. In the subgroup of patients with bronchiolitis or pneumonia, the sensitivity of the Directigen test (with reference to culture) was 91% (31 of 34), and in the subgroup with upper respiratory tract infection or asthma it was 77% (10 of 13). The specificity was the same in either group-91% (117 of 128 and 208 of 229).
The Becton Dickinson Directigen RSV test offers a specific and sensitive test for the rapid detection of RSV in NPA. Its high specificity of 90% and sensitivity of 83% compare well with those of other solid-phase EIA systems which require more stringent washing conditions and an automated spectrophotometer (2, 5, 10, 11) . The detection of RSV (in the Directigen test) in NPA which were subsequently culture negative for the virus may have been influenced by transport of the specimens and the period from the onset of illness before the patients were sampled. In our study population, the mean duration of illness before the NPA was collected from the patient was 2.7 days (standard deviation, ± 1.9) in the group which was Directigen and culture positive, compared with 3.4 days (standard deviation, ±2.4) in the group which was Directigen negative but culture positive. Various laboratories using the immunofluorescence test or EIA have also reported the detection of RSV (confirmed in blocking tests) in clinical specimens which were culture negative (4, 10, 12) .
The short assay time of 15 min could make this an efficient bedside test, in particular for antiviral chemotherapeutic purposes or for infection control within the hospital. However, enhanced performance after one freeze-thaw cycle suggested that longer contact with extraction buffer or more vigorous sample disruption might be of value, and the current directions for use of the product have been modified accordingly; at present, this requirement will restrict bedside use of the test. The small volume of specimen needed (0.25 ml) would still allow for other rapid viral tests (and culture) with the remaining portion of the NPA. However, as with all such tests, regular access to virus culture is highly desirable to allow continuous monitoring of test performance and isolation of viruses other than RSV.
